Grufity logoGrufity logo

EW

77.25USD+2.40(+3.21%)Market Closed

Edwards Lifesciences Corp

Market Summary

USD77.25+2.40Market Closed
3.21%

EW Alerts

EW Stock Price

RSI Chart

Valuation

Market Cap

43.9B

Price/Earnings

30.09

Price/Sales

8.18

Price/Cashflow

33.53

MarketCap/EBT

26.06

Price/Sales

Profitability

EBT Margin

31.40%

Return on Equity

23.46%

Return on Assets

16.89%

Fundamentals

Revenue

Revenue (TTM)

5.4B

Revenue Y/Y

0.67%

Revenue Q/Q

-4%

Earnings

Earnings (TTM)

1.5B

Earnings Y/Y

1%

Earnings Q/Q

-15.48%

Price Action

52 Week Range

67.13131.73
(Low)(High)

Last 7 days

1.8%

Last 30 days

6.7%

Last 90 days

-14.3%

Trailing 12 Months

-28.0%

Financial Health

Current Ratio

3.83

Investor Care

Buy Backs (1Y)

0.97%

Diluted EPS (TTM)

2.32

Peers (Alternatives to Edwards Lifesciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-13.49% 40.70%
185.5K
28.0K
144.70% 331.94%
115.4B
31.1B
-9.50% -24.43%
22.17
3.71
-1.67% 34.08%
86.7B
17.9B
2.03% -0.30%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
9.71% -16.63%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
5.67% 8.87%
38.21
3.25
-6.81% -14.96%
43.9B
5.4B
6.65% -28.01%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
10.28% 18.00%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
22.18% -14.71%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-14.46% 3.27%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-25.11% -67.28%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
20.80% 31.22%
-26.38
14.01
34.44% -10.05%
1.0B
795.9M
21.44% -10.84%
-131.34
1.33
8.11% 182.50%
994.0M
154.8M
-9.99% -44.52%
-10.57
6.72
60.29% -2309.58%
606.7M
236.2M
-2.98% -29.95%
-16.43
2.57
-8.79% -175.19%

Financials for Edwards Lifesciences

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue0.2%5,3645,3555,3575,2335,095
Gross Profit1.6%4,2324,1654,1023,9843,859
  S&GA Expenses0.8%1,5811,5681,5331,4941,408
  R&D Expenses-0.5%946950925903866
Earnings Before Taxes1.0%1,6841,6681,7491,7021,682
Net Income0.2%1,4591,4551,5391,5031,477
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets2.5%8,6388,4258,4208,5038,160
  Current Assets7.7%3,5143,2633,2413,1813,516
    Cash Equivalents4.5%1,2521,1981,0318631,507
  Inventory2.4%758740731727738
  Net PPE0.4%1,5661,5601,5521,5471,465
  Goodwill-0.5%1,1591,1641,1661,1681,170
Liabilities-2.5%2,4202,4822,5752,6672,619
  Current Liabilities-5.3%9189699501,032967
    LT Debt, Non Current0.0%596596596596596
Shareholder's Equity4.6%6,2185,9445,8455,8365,541
  Retained Earnings5.0%7,1926,8486,4426,0685,733
  Additional Paid-In Capital4.7%1,8531,7691,7001,643-
Accumulated Depreciation-655----
Shares Outstanding-0.1%619620621624624
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-14.5%1,3091,5311,7251,7321,758
  Share Based Compensation3.1%123119114109106
Cashflow From Investing17.9%-808.30-984.20-1,443.30-1,722.50-1,016.50
Cashflow From Financing-15.6%-808.10-699.20-450.10-356.30-252.90
  Buy Backs11.5%958859616513417

Risks

What is the probability of a big loss on EW?

33.5%


Probability that Edwards Lifesciences stock will be more than 20% underwater in next one year

25.8%


Probability that Edwards Lifesciences stock will be more than 30% underwater in next one year.

1.9%


Probability that Edwards Lifesciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EW drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Edwards Lifesciences was unfortunately bought at previous high price.

Returns

Cumulative Returns on EW

32.0%


10-Year Cumulative Returns

35.9%


7-Year Cumulative Returns

43.0%


5-Year Cumulative Returns

41.6%


3-Year Cumulative Returns

What are the long-term rolling returns for EW?

FIve years rolling returns for Edwards Lifesciences.

Which funds bought or sold EW recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
NEW
-
905,000
905,000
0.93%
2022-11-23
Toroso Investments, LLC
ADDED
5.52
-100,000
1,103,000
0.05%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
-10,167
66,000
0.04%
2022-11-22
CVA Family Office, LLC
REDUCED
-42.29
-134,000
134,000
0.04%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
4.96
-314,000
3,258,000
0.10%
2022-11-22
IHT Wealth Management, LLC
ADDED
26.02
66,000
754,000
0.06%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
4,874,000
4,874,000
0.06%
2022-11-21
FourThought Financial, LLC
ADDED
38.18
48,000
284,000
0.04%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.24
-14,244,000
86,223,000
0.15%
2022-11-21
17 CAPITAL PARTNERS, LLC
UNCHANGED
-
-52,000
339,000
0.46%

1–10 of 45

Latest Funds Activity

Are funds buying EW calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own EW

Edwards Lifesciences News

GuruFocus.com

Gurus Prescribed These Health.8 hours ago

GuruFocus.com

EW Fair Value

Recent SEC filings of Edwards Lifesciences

View All Filings
Date Filed Form Type Document
Nov 15, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 01, 2022
8-K
Current Report
Oct 28, 2022
10-Q
Quarterly Report
Oct 27, 2022
8-K
Current Report
Oct 14, 2022
4
Insider Trading
Oct 14, 2022
4
Insider Trading
Oct 11, 2022
4
Insider Trading

Latest Insider Trading transactions for EW

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-15
Chopra Daveen
SOLD
-296,720
74.18
-4,000
CVP, Surgical Structural Heart
2022-11-15
Chopra Daveen
ACQUIRED
181,107
45.2767
4,000
CVP, Surgical Structural Heart
2022-11-14
MUSSALLEM MICHAEL A
GIFTED
-
-
9,500
Chairman & CEO
2022-11-14
MUSSALLEM MICHAEL A
GIFTED
-
-
-9,500
Chairman & CEO
2022-11-14
MUSSALLEM MICHAEL A
ACQUIRED
1,033,900
35.1967
29,375
Chairman & CEO
2022-11-14
MUSSALLEM MICHAEL A
SOLD
-1,473,640
74.1452
-19,875
Chairman & CEO
2022-11-08
Wood Larry L
SOLD
-496,065
68.4983
-7,242
CVP, TAVR
2022-11-08
BOBO DONALD E JR
ACQUIRED
236,698
35.1967
6,725
CVP,Strategy/Corp Development
2022-11-08
BOBO DONALD E JR
SOLD
-460,394
68.46
-6,725
CVP,Strategy/Corp Development
2022-11-08
Wood Larry L
ACQUIRED
266,144
36.75
7,242
CVP, TAVR

1–10 of 50

Michael A. Mussallem
15700
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

EW Income Statement

2022-09-30
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net sales$ 1,319.0$ 1,310.2$ 4,034.1$ 3,902.8
Cost of sales253.8311.7822.5939.4
Gross profit1,065.2998.53,211.62,963.4
Selling, general, and administrative expenses377.3364.41,156.61,069.7
Research and development expenses233.6238.0713.0670.3
Intellectual property litigation (income) expenses, net(2.4)4.710.813.5
Change in fair value of contingent consideration liabilities, net (Note 7)(12.5)1.1(36.3)(106.0)
Special charge (Note 3)66.80.066.80.0
Operating income402.4390.31,300.71,315.9
Interest (income) expense, net(6.9)0.8(8.4)1.5
Other expense (income), net2.0(1.4)1.0(11.3)
Income before provision for income taxes407.3390.91,308.11,325.7
Provision for income taxes63.850.8184.6157.9
Net income$ 343.5$ 340.1$ 1,123.5$ 1,167.8
Earnings per share:    
Basic (in dollars per share)$ 0.55$ 0.55$ 1.81$ 1.87
Diluted (in dollars per share)$ 0.55$ 0.54$ 1.79$ 1.85
Weighted-average number of common shares outstanding:    
Basic (in shares)619.8623.6621.0623.0
Diluted (in shares)624.5631.7626.9631.0

EW Balance Sheet

2022-09-30
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 1,247.8$ 862.8
Short-term investments (Note 4)490.9604.0
Accounts receivable, net of allowances of $7.5 and $9.3, respectively618.1582.2
Other receivables43.382.7
Inventories (Note 2)757.8726.7
Prepaid expenses88.485.2
Other current assets267.6237.1
Total current assets3,513.93,180.7
Long-term investments (Note 4)1,381.01,834.2
Property, plant, and equipment, net1,566.41,546.6
Operating lease right-of-use assets87.792.1
Goodwill1,158.71,167.9
Other intangible assets, net (Note 3)266.5323.6
Deferred income taxes347.5246.7
Other assets (Note 5)316.5110.8
Total assets8,638.28,502.6
Current liabilities  
Accounts payable154.9204.5
Accrued and other liabilities (Note 2)739.5802.3
Operating lease liabilities23.525.5
Total current liabilities917.91,032.3
Long-term debt596.2595.7
Contingent consideration liabilities (Note 7)25.762.0
Taxes payable142.9190.0
Operating lease liabilities67.169.1
Uncertain tax positions295.6259.0
Litigation settlement accrual (Note 2)153.9191.3
Other liabilities221.1267.3
Total liabilities2,420.42,666.7
Commitments and contingencies (Note 11)
Stockholders' equity  
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding          0.00.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 645.7 and 642.0 shares issued, and 619.4 and 624.1 shares outstanding, respectively645.7642.0
Additional paid-in capital1,914.51,700.4
Retained earnings7,191.66,068.1
Accumulated other comprehensive loss (Note 12)(256.0)(157.7)
Treasury stock, at cost, 26.3 and 17.9 shares, respectively(3,278.0)(2,416.9)
Total stockholders' equity6,217.85,835.9
Total liabilities and stockholders' equity$ 8,638.2$ 8,502.6